Abstract: A software analysis system collects a first set of time series counter values from an original version of software instrumented with software telemetry counters, and collects a second set of time series counter values from a modified version of the software that also is instrumented with the software telemetry counters. The first time series become dimensions input to train a weight matrix of a first self-organizing map, to cause the first self-organizing map to cluster the time series into a group of first clusters describing execution of the original software. The second time series become dimensions input to train a weight matrix of a second self-organizing map, to cause the second self-organizing map to cluster the time series into a group of second clusters describing execution of the modified software. Deviation analysis between the first and second groups of clusters is used to identify execution differences between the software versions.

Abstract: A method of predicting usage levels of solid-state drives (SSDS) includes receiving time series usage data from each SSD over a plurality of monitoring intervals (lags), and using a first portion of the time series usage data to train (fit) an ARIMA model to the time series data. A unique ARIMA model (order) is determined for each SSD from the unique time series % usage data of each SSD. The ARMIA model is then fit to the time series % usage data and used in a predictive manner to predict a future date when the % usage will exceed a threshold % usage value. By predicting when the SSDs will meet particular thresholds, it is possible to plan for and procure replacement SSDs to enable currently installed SSDs to be removed from service before the currently installed SSD % usage levels exceed threshold values, thus enabling the currently installed SSDs to be repurposed.

Abstract: Aspects of the present disclosure relate to detecting and correcting a storage array's drive sectors to prevent data loss. In embodiments, a storage array's telemetry information is monitored. Further, one or more state or operational metrics of the storage array's storage drives are measured. Additionally, each storage drive is scrubbed based on each drive's relative scrubbing priority defined by the telemetry information and each storage drive's state or operation metrics.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: A method of predicting usage levels of solid-state drives (SSDS) includes receiving time series usage data from each SSD over a plurality of monitoring intervals (lags), and using a first portion of the time series usage data to train (fit) an ARIMA model to the time series data. A unique ARIMA model (order) is determined for each SSD from the unique time series % usage data of each SSD. The ARMIA model is then fit to the time series % usage data and used in a predictive manner to predict a future date when the % usage will exceed a threshold % usage value. By predicting when the SSDs will meet particular thresholds, it is possible to plan for and procure replacement SSDs to enable currently installed SSDs to be removed from service before the currently installed SSD % usage levels exceed threshold values, thus enabling the currently installed SSDs to be repurposed.

Abstract: An amount of storage space required to maintain counter information for a storage system is reduced without reducing a temporal granularity or tracking granularity of the counter information. Rather than periodically recording actual (i.e., raw) counter values for counters, difference (i.e., delta) values may be recorded. For a given counter, a difference (delta value) between a value of the counter for a given point in time (PIT) and a value of the counter for a previous PIT may be determined, and this delta value may be stored as opposed to storing the raw counter value. This delta value may be a significantly smaller value than the raw value. To further reduce the amount of storage space required, no value may be stored for a counter for a given PIT if it is determined that there is no difference between a counter value for the given PIT and a previous PIT.

Abstract: Aspects of the present disclosure relate to detecting and correcting a storage array's drive sectors to prevent data loss. In embodiments, a storage array's telemetry information is monitored. Further, one or more state or operational metrics of the storage array's storage drives are measured. Additionally, each storage drive is scrubbed based on each drive's relative scrubbing priority defined by the telemetry information and each storage drive's state or operation metrics.

Abstract: An amount of storage space required to maintain counter information for a storage system is reduced without reducing a temporal granularity or tracking granularity of the counter information. Rather than periodically recording actual (i.e., raw) counter values for counters, difference (i.e., delta) values may be recorded. For a given counter, a difference (delta value) between a value of the counter for a given point in time (PIT) and a value of the counter for a previous PIT may be determined, and this delta value may be stored as opposed to storing the raw counter value. This delta value may be a significantly smaller value than the raw value. To further reduce the amount of storage space required, no value may be stored for a counter for a given PIT if it is determined that there is no difference between a counter value for the given PIT and a previous PIT.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: An aspect of the present disclosure relates to one or more techniques to identify and resolve storage array errors. In embodiments, an error notification related to a computing device can be received. One or more threads related to the error notification can further be identified. Additionally, an error resolution technique can be performed based on each identified thread.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

Abstract: The present invention relates to an immediate release solid oral pharmaceutical composition comprising an effective amount of Tizanidine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof. The solid oral dosage form comprises one or more methacrylic acid copolymers or its derivatives and is bioequivalent to the commercially available counterpart (ZANAFLEX® capsule) after oral administration. The invention also relates to a process for preparation of a pharmaceutical capsule dosage form comprising an effective amount of Tizanidine Hydrochloride wherein, the dosage form comprises methacrylic acid copolymer or its derivatives.

Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.